文献速递眼底病与葡萄膜炎

氟轻松醋酸酯玻璃体内植入剂对慢性非感染性后葡萄膜炎复发率的影响:12个月结果

Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
PubMed 文献 · Ophthalmology · 2018-10-25

结果显示FA组6个月和12个月葡萄膜炎复发率显著低于假注射组,且视力下降≥15字母的发生率、全身和局部辅助治疗使用率均更低,但白内障发生率更高。

要点

  • FA植入剂组6个月和12个月复发率分别为28%和91%对应的假注射组,均显著更低(P<0.001)。
  • FA组每只研究眼平均复发次数0.7次,假注射组2.5次。
  • FA组视力下降≥15字母发生率为14%,假注射组为31%。

核心结论

  • 在复发性非感染性后葡萄膜炎患者中,FA植入剂较假注射显著降低6个月和12个月复发率,减少辅助治疗需求并减少视力下降,但白内障发生率更高。

研究设计与样本

  • 多中心、随机、前瞻性、双盲、假注射对照的3年3期临床试验。
  • 双眼患病者选取病情更重的眼作为研究眼。
  • FA植入剂剂量为0.18 mg,注射入玻璃体腔;假注射模拟植入剂递送过程。
  • 主要结局指标为6个月复发率。

主要发现

  • 6个月复发率FA组28%、假注射组91%,12个月复发率FA组38%、假注射组98%,差异均显著(P<0.001)。
  • 每只研究眼平均复发次数FA组0.7次,假注射组2.5次。
  • 最佳矫正视力下降≥15字母的发生率FA组14%,假注射组31%。
  • 全身葡萄膜炎辅助治疗使用率FA组19%、假注射组40%;局部辅助治疗使用率FA组7%、假注射组62%。
  • FA组白内障发生率更高;眼压降压治疗使用两组相似;截至12个月未观察到死亡、治疗相关研究终止或非预期安全性信号。

关键数值与推荐

  • 6个月复发率:FA组28% vs 假注射组91%(P<0.001)。
  • 12个月复发率:FA组38% vs 假注射组98%(P<0.001)。
  • 每只研究眼平均复发次数:FA组0.7次 vs 假注射组2.5次。
  • 最佳矫正视力下降≥15字母发生率:FA组14% vs 假注射组31%。
  • 全身辅助治疗使用率:FA组19% vs 假注射组40%;局部辅助治疗使用率:FA组7% vs 假注射组62%。

临床怎么用

  • FA植入剂可用于管理慢性非感染性后葡萄膜炎相关的炎症,减少复发和辅助治疗需求。
  • 注射递送方式未增加眼部不良事件或局部激素使用以外的安全性问题,适合在诊室环境中操作。
  • 治疗时需关注白内障发生风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety and efficacy of an intravitreal fluocinolone acetonide (FA) insert to manage inflammation associated with chronic noninfectious posterior uveitis. DESIGN: Multicenter, randomized, prospective, doubled-masked, sham-controlled, 3-year phase 3 clinical trial. PARTICIPANTS: One hundred twenty-nine participants with recurrent noninfectious posterior uveitis were assigned randomly to FA insert (n = 87) or sham injection (n = 42). The more severely affected eye in participants with bilateral disease was designated as the study eye. METHODS: The insert (FA, 0.18 mg) was injected into the vitreous cavity; sham injection mimicked the insert delivery procedure. Ophthalmic examinations, OCT, and ocular tolerability and discomfort assessments were conducted; study visits were on days 7 and 28 and months 2, 3, 6, 9, and 12. Uveitis recurrence was treated as needed. The 6-month recurrence rate was the primary outcome measure. RESULTS: The 6-month (28% and 91%) and 12-month (38% and 98%) uveitis recurrence rates were significantly lower (P < 0.001) with FA insert vs. sham, respectively. Fewer recurrences per study eye (mean, 0.7 vs. 2.5), lower incidence of 15-letter or more decrease in best-corrected visual acuity (14% vs. 31%), and reduced systemic (19% vs. 40%) and local (7% vs. 62%) uveitis adjunctive treatments were observed with FA insert vs. sham, respectively. The FA insert group showed higher rates of cataract. Intraocular pressure-lowering treatment use was similar between groups. No deaths, treatment-related study discontinuations, or unanticipated safety signals were observed through 12 months. CONCLUSIONS: Chronic noninfectious posterior uveitis was managed successfully in this study population; FA insert eyes experienced fewer uveitis recurrence episodes, required fewer adjunctive treatments, and demonstrated less visual acuity loss compared with sham eyes. The FA insert treatment group showed higher rates of cataract; delivery by injection was not associated with an increase in ocular adverse events or any other safety measures not typically associated with local steroid use, suggesting the procedure is appropriate for an office setting.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. Ophthalmology. 2018. PMID: 30367884. doi:10.1016/j.ophtha.2018.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。